The GLIOMATCH project has officially started in January 2024
Under the coordination of KU Leuven, the multidisciplinary consortium will be working on pioneering personalised therapies for brain cancer patients.
GLIOMATCH selected for Horizon Europe funding
The GLIOMATCH project aimed at advancing precision medicine for brain cancer patients has received a total funding of €12.59 million from the EU, Switzerland, and the UK.